ROS1 and non-small cell lung carcinoma: Here we reported preclinical data for iruplinalkib, a novel ATP-competitive ALK/ROS1 inhibitor, the efficacy and safety of which were currently evaluated in patients who have not been treated with ALK-positive NSCLC in a phase III clinical trial (NCT04632758).